Moderna (NASDAQ:MRNA) Rating Reiterated by William Blair

Moderna (NASDAQ:MRNA)‘s stock had its “market perform” rating restated by analysts at William Blair in a report issued on Thursday, RTT News reports.

MRNA has been the subject of a number of other reports. Oppenheimer boosted their price target on Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, June 12th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Monday, June 3rd. Piper Sandler reiterated an “overweight” rating and set a $214.00 price target on shares of Moderna in a research note on Thursday. Canaccord Genuity Group upped their price objective on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research note on Friday, May 3rd. Finally, Royal Bank of Canada lifted their target price on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research report on Monday, June 3rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and a consensus target price of $134.02.

Moderna Trading Down 1.0 %

Moderna stock traded down $1.27 during mid-day trading on Thursday, reaching $121.18. 4,779,127 shares of the company traded hands, compared to its average volume of 4,202,933. The firm’s 50 day moving average price is $133.40 and its 200 day moving average price is $111.40. Moderna has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The firm has a market capitalization of $46.44 billion, a price-to-earnings ratio of -7.74 and a beta of 1.54.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same period in the prior year, the firm earned $0.19 EPS. The company’s revenue was down 91.0% compared to the same quarter last year. On average, analysts anticipate that Moderna will post -7.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $101.68, for a total transaction of $1,525,200.00. Following the transaction, the director now owns 2,086,931 shares in the company, valued at approximately $212,199,144.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $101.68, for a total transaction of $1,525,200.00. Following the completion of the sale, the director now owns 2,086,931 shares of the company’s stock, valued at $212,199,144.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James M. Mock sold 705 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the completion of the transaction, the chief financial officer now owns 5,048 shares in the company, valued at approximately $514,542.64. The disclosure for this sale can be found here. Insiders have sold a total of 396,255 shares of company stock worth $54,210,631 in the last ninety days. 15.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Quadrant Capital Group LLC boosted its position in Moderna by 7.5% during the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock worth $266,000 after purchasing an additional 187 shares in the last quarter. International Assets Investment Management LLC grew its stake in Moderna by 6,528.9% in the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock valued at $38,552,000 after acquiring an additional 381,808 shares during the period. abrdn plc increased its holdings in Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after acquiring an additional 399,843 shares in the last quarter. Ontario Teachers Pension Plan Board acquired a new position in Moderna during the fourth quarter worth $1,358,000. Finally, Hobbs Group Advisors LLC purchased a new position in Moderna during the fourth quarter valued at $664,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.